The Consortium of Food Allergy Research (CoFAR) was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies.
A food allergy is an immunological disease that is responsible for substantial morbidity and mortality. Food allergies occur in 6-8% of children and 2% of adults, and prevalence is increasing. Severe food allergic reactions may cause anaphylaxis and/or death.
Closed to Enrollment
In July 2006, we began enrollment into our first study which is an Observational study of food allergy (CoFAR2). The study is researching the development of peanut allergy in infants (3 to 15 months in age) with known milk or egg allergy.
Egg Oral Immunotherapy (CoFAR3) opened in July 2007. This 2 year treatment study is investigating the outcome in egg allergic individuals (6 to 18 years) who receive a powdered egg product or placebo by mouth.
Peanut Sublingual Immunotherapy (CoFAR4) opened in April 2008. This 4 year treatment study is investigating the outcome in peanut allergic individuals (12-40 years) who receive a liquid peanut product or placebo under the tongue.
EMP-123 (CoFAR1) opened in March 2009. This is a 7 month first in human Phase I trial investigating the safety and possible side effects of a peanut vaccine in healthy volunteers first and then in peanut allergic subjects (18-40 years).
Eosinophilic Esophagitis Databank (CoFAR5) opened in April 2011. This is a one visit study, collecting blood and medical history. The purpose is to investigate the genetic components of Eosinophilc Esophagitis through multiple genetic analyses in subjects 6 months old through 65 years.
Baked Egg versus Egg Oral Immunotherapy (CoFAR7) opened in June 2013. This 2 year treatment study is investigating the outcome in egg allergic individuals (3 to 16 years) who receive food containing baked egg or a powdered egg product.
Peanut Epicutaneous Immunotherapy (CoFAR6) opened to enrollment in September 2013. Participation for this study is up to 4 ½ years. This treatment study is investigating the outcome in peanut allergic individuals (4-25 years) who apply a peanut protein patch or placebo patch to the skin.
Interested families can get more information by contacting a Study Coordinator at a participating site: Contact a Site